|Bid||3.6000 x 800|
|Ask||0.0000 x 800|
|Day's Range||3.5000 - 3.6950|
|52 Week Range||2.3200 - 6.8900|
|Beta (3Y Monthly)||1.53|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jun 9, 2017 - Jun 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
On a per-share basis, the New York-based company said it had a loss of 18 cents. The life sciences and biotechnology company posted revenue of $19.3 million in the period. In the final minutes of trading ...
Enzo Biochem, Inc. , an integrated diagnostics and therapeutics company, today reported results for the fiscal quarter and first half ended January 31, 2019 along with providing more detail on its investments in the development of novel diagnostic system and centralized clinical services.
To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024. A rebroadcast of the call will be available starting approximately two hours after the conference call ends, through 12 AM (E.T.) Tuesday March 26, 2019.
In 1976 Elazar Rabbani was appointed CEO of Enzo Biochem, Inc. (NYSE:ENZ). First, this article will compare CEO compensation with compensation at similar sized companies. Next, we'll consider growth thatRead More...
NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
The New York-based company said it had a loss of 13 cents per share. The life sciences and biotechnology company posted revenue of $21.3 million in the period. In the final minutes of trading on Monday, ...
Enzo Biochem, Inc. , an integrated diagnostic and therapeutics company, will hold a conference call to discuss fiscal 2019 first quarter results Tuesday, December 11, 2018, at 8:30 AM E.T.
Enzo Biochem, Inc. (ENZ), an integrated diagnostics and therapeutics company, today reported the publication of a study in the Journal of Lipid Research by researchers at a collaborating institution that shows SK1-I, the company’s proprietary Sphingosine Kinase 1 inhibitor drug candidate, was effective in reversing resistance to the breast cancer drug tamoxifen in a tamoxifen-resistant human breast cancer cell line. As pointed out in the publication, endocrine therapy, such as tamoxifen, is a first line treatment for estrogen receptor-positive breast cancer patients.
The big shareholder groups in Enzo Biochem Inc (NYSE:ENZ) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders own Read More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 16) Endo International PLC (NASDAQ: ENDP ) Krystal Biotech ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 15) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ...
NEW YORK, NY / ACCESSWIRE / October 16, 2018 / Enzo Biochem, Inc. (NYSE: ENZ ) will be discussing their earnings results in their 2018 FourthQuarter Earnings to be held on October16, 2018 at 8:30 AM Eastern ...
NEW YORK (AP) _ Enzo Biochem Inc. (ENZ) on Monday reported a fiscal fourth-quarter loss of $5.8 million, after reporting a profit in the same period a year earlier. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research.
Molecular Assay Approvals from New York State Department of Health and Planned Acquisition of New Facility Highlight Progress Advancing Growth Strategy
To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024. A rebroadcast of the call will be available starting approximately two hours after the conference call ends, through 12 AM (E.T.) Tuesday October 30, 2018.
Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Given Celgene's solid long-term track record, the lackluster year-to-date performance may represent a buying opportunity.
Enzo Biochem, Inc. (ENZ), an integrated diagnostic and therapeutics company, announced today that, as part of implementing its growth strategy, it has entered into an agreement to purchase a commercial facility with nearly 36,000 square feet in Farmingdale, NY. The building is adjacent to the Company’s current Long Island campus and enhances the infrastructure needed to produce and distribute Enzo’s expanding low cost, diagnostic platform products and related services. The Company’s platform development includes automation-compatible reagent systems and associated products for sample collection and processing through analysis.